Patent US4661104A successfully refreshed from Google Patents.
US4661104A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Active compound release systems
Assignee: Bayer AG
•
Filing: 1984-12-14
•
Granted: 1987-04-28
•
Expires: 2004-12-14
Abstract
Abstract In a therapeutic system such as a plaster for administration of an active compound through the skin and comprising a covering layer which is essentially impermeable to the active compound, an active compound reservoir layer and a protective layer which can be pulled off and which is essentially impermeable to the active compound, the improvement wherein the reservoir layer contain about 1-30% of active compound in an elastomer mixture comprising a predominantly amorphous olefinic (co)polymer with a glass transition temperature of <20 DEG C., mixed with from 0 up to about 50% by weight of a polyisobutylene, polybutadiene oil and/or paraffin oil, and a tackifying resin. Thereby the active compound can be released in regulated relatively large quantity over a prolonged period of time.
Inventors
- 👤 Miklos von Bittera
- 👤 Rolf-Volker Meyer
- 👤 Rolf Dhein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 01:37
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/02; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K9/7076; Y; Y10; Y10T; Y10T428/00; Y10T428/24; Y10T428/24479
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
189 words
In a therapeutic system including an active compound, an upper covering layer that is essentially impermeable to the active compound, an active compound reservoir layer and a protective layer that can be pulled off and that is essentially impermeable to the active compound, the improvement which comprises the reservoir layer containing 1 to 30% of an active compound, said active compound being an antiphlogistic agent in an elastomeric mixture, said elastomic mixture comprising predominantly amorphous olefinic polymers or copolymers, said polymers or copolymers having glass transition temperatures of less than 20° C., the mixture containing (a) (i) two different (C 2 -C 18 ) α-olefins or cycloolefins, (ii) or the mixture containing two different (C 2 -C 18 ) α-olefins or cycloolefins copolymerized with a diolefin alone, with up to 95% by weight of the total amount of polymer being a diene rubber or a diene rubber copolymerized with an α-olefin, said diene rubber-containing copolymer having a molecular weight from 20,000 to 1×10 6 g/mole, (b) an entraining agent selected from the group consisting of polyisobutylene oil, polybutadiene oil, paraffin oil and mixtures thereof and (c) a tackifying resin.
Claim 2
Dependent Claim
189 words
In a therapeutic system including an active compound, an upper covering layer that is essentially impermeable to the active compound, an active compound reservoir layer and a protective layer that can be pulled off and that is essentially impermeable to the active compound, the improvement which comprises the reservoir layer containing 1 to 30% of an active compound, said active compound being an antiphlogistic agent in an elastomeric mixture, said elastomic mixture comprising predominantly amorphous olefinic polymers or copolymers, said polymers or copolymers having glass transition temperatures of less than 20° C., the mixture containing (a) (i) two different (C 2 -C 18 ) α-olefins or cycloolefins, (ii) or the mixture containing two different (C 2 -C 18 ) α-olefins or cycloolefins copolymerized with a diolefin alone, with up to 95% by weight of the total amount of polymer being a diene rubber or a diene rubber copolymerized with an α-olefin, said diene rubber-containing copolymer having a molecular weight from 20,000 to 1×10 6 g/mole, (b) an entraining agent selected from the group consisting of polyisobutylene oil, polybutadiene oil, paraffin oil and mixtures thereof and (c) a tackifying resin.
Claim 3
Dependent Claim
24 words
A therapeutic system according to claim 1, wherein as the active compound is 2 to 30% by weight of an antiphogistic in the reservoir.
Claim 4
Dependent Claim
40 words
A therapeutic system according to claim 2, wherein the reservoir containing active compound comprises about 30-60% by weight of polymer or copolymer, 30-60% by weight of entraining agent and 2-40% by weight of resin, in addition to the active compound.
Claim 5
Dependent Claim
36 words
A therapeutic system according to claim 1, wherein the polymer or copolymer comprises an EPDM rubber comprising about 20-90% by weight of ethylene, 10-80% by weight of propylene and 2-15% by weight of a non-conjugated diene.
Claim 6
Dependent Claim
13 words
A therapeutic system according to claim 1, wherein the polymer comprises a polyoctenamer.
Claim 7
Dependent Claim
18 words
A therapeutic system according to claim 4, wherein the polymer or copolymer is mixed with a diene rubber.
Claim 8
Dependent Claim
23 words
A therapeutic systems according to claim 2, wherein the entraining agent comprises at least one of a paraffin oil and liquid polybutadiene oil.
Claim 9
Dependent Claim
109 words
A therapeutic system according to claim 1, wherein the active compound is selected from the group consisting of antiphlogistics of the formula ##STR5## in which R 1 -R 5 each independently is hydrogen, halogen, lower alkyl or substituted alkyl, X is N or CH, Y is hydrogen, a metal ion, alkyl or substituted alkyl, R is hydrogen, lower alykyl or substituted alkyl, Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl, n and m each is an integer and together total zero, 1 or 2, and p is zero or 1, with the proviso that Ar is not aryl or heteroaryl if n, m and p each is zero.
Claim 10
Dependent Claim
12 words
A system according to claim 1, wherein the active compound is etofenamat.
Claim 11
Dependent Claim
12 words
A system according to claim 1, wherein the active compound is ketoprofen.
Claim 12
Dependent Claim
12 words
A system according to claim 1, wherein the active compound is acematacin.
Claim 13
Dependent Claim
12 words
A system according to claim 1, wherein the active compound is indoprofen.
Claim 14
Dependent Claim
12 words
A system according to claim 1, wherein the active compound is indometacin.
Claim 15
Dependent Claim
22 words
A treatment system according to claim 1, wherein the active compound is contained in an amount of 2 to 20% by weight.
Claim 16
Dependent Claim
22 words
A therapeutic system according to claim 1, wherein the entraining agent is contained in an amount of up to 50% by weight.
Claim 17
Dependent Claim
27 words
A therapeutic system according to claim 1, wherein the polymer or copolymer is selected from the group consisting of amorphous polypropylene, amorphous polybut-1-ene, polyoctenamers and ethylene/propylene copolymers.
Claim 18
Dependent Claim
18 words
A therapeutic system according to claim 1, wherein the α-olefin is a C 4 to C 18 α-olefin.
Claim 19
Dependent Claim
18 words
A therapeutic system according to claim 1, wherein the α-olefin is a C 4 to C 12 α-olefin.
Claim 20
Dependent Claim
18 words
A therapeutic system according to claim 4, wherein the weight % of the propylene is 4 to 10%.
Claim 21
Dependent Claim
22 words
A therapeutic system according to claim 4, wherein the non-conjugated diene is selected from the group consisting of cyclopentadiene, ethyldene-norbornene and hexa-1,4-diene.
Claim 22
Dependent Claim
16 words
A therapeutic system according to claim 4, wherein the molecular weight is up to 500,000 g/mol.
Claim 23
Dependent Claim
32 words
A therapeutic system according to claim 1, wherein the diene rubber is prepared on the basis of a diene which is selected from the group consisting of butadiene, isoprene, piperylene and 2,3-dimethylbutadiene.
Claim 24
Dependent Claim
17 words
A therapeutic system according to claim 1, wherein the diene rubber has more than 80% of cis-1,4-linkages.
Claim 25
Dependent Claim
34 words
A thereapeutic system according to claim 1, wherein a vinyl aromatic is combined with the diene rubber, said vinyl aromatic being selected from the group consisting of styrene, α-methylstyrene, vinyltoluenes, p-ethylstyrene, dimethylstyrenes and 4-vinyldiphenyl.
References Cited (Backward Citations)
DE132690C
Cited
US3742951B1
Cited
US3742951A
Cited
US3996934A
Cited
DE2604718A1
Cited
US4031894A
Cited
US4201211A
Cited
GB2021950A
Cited
DE3007368A1
Cited
US4455146A
Cited
JPS562909A
Cited
GB2073588A
Cited
DE3111734A1
Cited
DE3119752A1
Cited
FR2497457A1
Cited
DE3200369A1
Cited
GB2095108A
Cited
US4420407A
Cited
DE3317285A1
Cited
DE3319469A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-04-27 | 1990-10-27 | 1991-04-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-04-27 | 1994-10-27 | 1995-04-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-04-27 | 1998-10-27 | 1999-04-28 | $7700.00 | Window Closed / Lapsed |